NCT00513110View on ClinicalTrials.gov

A Possible Therapeutic Role for Adenosine During Inflammation

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Endotoxemia
Interventions
GENETIC

AMPD1 polymorphism

Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism

DRUG

Caffeine infusion

Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.

DRUG

placebo

Endotoxin 2ng/kg combined with saline infusion (0.9%)

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Centre, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT00513110 - A Possible Therapeutic Role for Adenosine During Inflammation | Biotech Hunter | Biotech Hunter